Clinical Trials Logo

Opioid Addiction clinical trials

View clinical trials related to Opioid Addiction.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04336293 Completed - Cocaine Addiction Clinical Trials

sTMS for Substance Use-disordered Veterans

Start date: September 7, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if synchronized transcranial magnetic stimulation is safe and tolerable in individuals with cocaine, opioid, or alcohol use disorders.

NCT ID: NCT03685162 Completed - Opioid Addiction Clinical Trials

Observational Study to Evaluate Levomethadone Safety and Effectiveness in Subjects Under Opioid Maintenance Treatment

LEVOPROACT
Start date: February 27, 2018
Phase:
Study type: Observational

Multicentre, prospective, observational, non-interventional, open- ended trial, collecting data from male and female patients aged ≥ 18 years, with a diagnosis of opioid addiction according to ICD-10 (F11.2), treated with therapeutic doses of levomethadone according to the routine medical practice.

NCT ID: NCT02696096 Completed - Opioid Addiction Clinical Trials

Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence

Start date: August 2016
Phase: Phase 3
Study type: Interventional

This study proposes to use functional magnetic resonance imaging (FMRI) to observe brain activity and behavior associated with decision-making about rewards (DD task), working memory and working memory cognitive persistence (WM task), and craving (CR task) in 72 opiate dependent participants initiating buprenorphine. While stably using opiates (initial study appointment) and again during withdrawal (approximately 3 days later), participants will receive an FMRI scan with behavioral challenges; immediately after the second FMRI, they will receive their first dose of buprenorphine. Buprenorphine treatment will continue for twelve weeks, followed by a four week taper. Urine toxicological analysis will be performed prior to the first scanning session, weekly for two weeks and biweekly thereafter. Participation for all individuals will last 4 months. Assessments will occur at baseline, and weeks 1, 2, 4, 8, and 12. Buprenorphine induction will begin at the completion of the second scan; follow-up medical visits will align with study assessments on weeks 1, 2, 4, 8 and 12. All participants will receive 16 weeks of buprenorphine (the final 4 of these 16 weeks will include a taper).

NCT ID: NCT01873989 Completed - Chronic Pain Clinical Trials

Testosterone Replacement for Male Opioid Agonist Maintained Patients

Start date: April 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to develop an effective treatment intervention for chronic pain, symptomatic hypogonadism, and opioid addiction

NCT ID: NCT01590251 Completed - Chronic Pain Clinical Trials

Yoga for Pain and Opioid Dependence

Yoga
Start date: April 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This study is designed to develop an effective adjunctive treatment using yoga for chronic pain and opioid dependence.

NCT ID: NCT01188421 Completed - Opioid Dependence Clinical Trials

Medications Development for Drug Abuse Disorders

Start date: October 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study of tramadol as an agent for short-term opioid withdrawal treatment. A randomized, double blind clinical trial comparing the efficacy and safety of tramadol to clonidine and buprenorphine in the short-term treatment of opioid withdrawal will be conducted. Opioid dependent participants will be treated on a residential unit. The primary outcome measure is opioid withdrawal symptoms.

NCT ID: NCT00499746 Completed - Opioid Abuse Clinical Trials

The Discriminative Effects of Tramadol in Humans

Start date: November 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.